Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile

Intravesical Ty21a Treatment of Non–muscle-invasive Bladder Cancer Shows a Good Safety Profile

Standard-of-care immunotherapy for non–muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmettte-Guérin (BCG) is associated with adverse events (AEs), disease recurrence/progression, and supply shortages. Preclinical data have shown that intravesical instillation of Ty21a/Vivotif,...

Full description

Bibliographic Details
Main Authors: Ilaria Lucca, Laurent Derré, Valérie Cesson, Perrine Bohner, François Crettenand, Sonia Rodrigues-Dias, Florence Dartiguenave, Audrey Masnada, Carla Texeira-Pereira, Sulayman Benmerzoug, Mathieu Chevalier, Sonia Domingos-Pereira, Sylvain Nguyen, Lenka Polak, Anna Schneider, Beat Roth, Patrice Jichlinski, Denise Nardelli-Haefliger
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:European Urology Open Science
Subjects:
Intravesical microbial immunotherapy
Non–muscle-invasive bladder cancer
Phase 1 trial
Salmonella Ty21a
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168322019048

Internet

http://www.sciencedirect.com/science/article/pii/S2666168322019048

Similar Items